← Russell 3000 cross-section

CAMP Camp4 Therapeutics Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$276m
Revenue TTM
$4m
Net income TTM
$-107m
Free cash flow
$-29m
Composite score
Sector rank
#2716

Valuation

P / E
EV / EBITDA
EV / sales
44.9
FCF yield
-10.42%
Earnings yield vs 10-yr
-43.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2,543.7%
EBITDA margin
-1,211.0%
ROE
15,475.3%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.83m
Buyers
4
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations Comparison of the Three Months Ended June 30, 2026 and 2025 The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025 (in thousands): Research and Collaboration Revenue We recognized $1.8 million in research and collaboration revenue during the three months ended June 30, 2026, compared to $1.5 million during the three months ended June 30, 2025. The increase of $0.5 million was primarily driven by higher personnel-related costs of $0.5 million due to increased stock-based compensation expense and an increase of $0.4 million in clinical and preclinical costs as we continue to advance CMP-002, including entering into contr …Camp4 Therapeutics Corp, 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →